Clorox Company (CLX) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 3, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q3 FY2026, filed Apr 30, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the CLX SEC filings page.
Clorox Company (CLX) reported $6.8B in revenue over the twelve months to Mar 31, 2026, down 3.7% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Clorox’s 2025 recovery came from lower product costs and better cash conversion, while shareholder distributions exceeded free cash flow.
Revenue was virtually unchanged at$7.1B across the latest two years, so the improved profitability was not volume-led. Gross margin rose from43.0% to45.2% , pointing to better cost control or product mix rather than scale alone.
Net income reached
Total liabilities were
Financial Health Signals
Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Clorox Company's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Not available for Clorox Company, and counted as zero in the overall score.
Clorox Company's revenue grew a modest 0.2% year-over-year to $7.1B. This slow but positive growth earns a score of 24/100.
Clorox Company has elevated debt relative to equity (D/E of 7.74), meaning the company relies heavily on borrowed funds. This high leverage results in a low score of 6/100, reflecting increased financial risk.
Clorox Company's current ratio of 0.84 is below the typical benchmark, resulting in a score of 13/100. This tight liquidity could limit financial flexibility if cash inflows slow.
Clorox Company converts 10.7% of revenue into free cash flow ($761.0M). This strong cash generation earns a score of 65/100.
Not available for Clorox Company, and counted as zero in the overall score.
Clorox Company passes 7 of 9 financial strength tests. All 4 profitability signals pass (positive income, cash flow, and earnings quality), 1 of 3 leverage/liquidity signals pass, both operating efficiency signals pass.
For every $1 of reported earnings, Clorox Company generates $1.21 in operating cash flow ($981.0M OCF vs $810.0M net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.
Key Financial Metrics
Earnings & Revenue
Clorox Company generated $1.7B in revenue in Q3 2026. This represents an increase of 0.1% from the same quarter a year earlier. Against the prior quarter it is down 0.2%.
Clorox Company reported $187.0M in net income in Q3 2026. This represents an increase of 0.5% from the same quarter a year earlier. Against the prior quarter it is up 19.1%.
Clorox Company earned $1.54 per diluted share (EPS) in Q3 2026. This represents an increase of 2.7% from the same quarter a year earlier. Against the prior quarter it is up 19.4%.
Not reported for Q3 2026.
Cash & Balance Sheet
Clorox Company recorded an outflow of $165.0M in free cash flow in Q3 2026, representing a cash shortfall after capex. This represents a decrease of 170.8% from the same quarter a year earlier. Against the prior quarter it is down 161.3%.
Clorox Company held $1.2B in cash against $2.5B in long-term debt as of Q3 2026.
Clorox Company paid $1.24 per share in dividends in Q3 2026. This represents an increase of 1.6% from the same quarter a year earlier. It is unchanged from the prior quarter.
Margins & Returns
Clorox Company's gross margin was 43.2% in Q3 2026, indicating the percentage of revenue retained after direct costs. This is down 1.4 percentage points from the same quarter a year earlier. Against the prior quarter it is up 0.1 percentage points.
Clorox Company's net profit margin was 11.2% in Q3 2026, showing the share of revenue converted to profit. This is up 0.1 percentage points from the same quarter a year earlier. Against the prior quarter it is up 1.8 percentage points.
Not reported for Q3 2026.
Not reported for Q3 2026.
Capital Allocation
Clorox Company invested $27.0M in research and development in Q3 2026. That is unchanged from the same quarter a year earlier. Against the prior quarter it is down 6.9%.
Clorox Company repurchased no shares in Q3 2026. Against the prior quarter it is down 100.0%.
Clorox Company invested $43.0M in capex in Q3 2026, funding long-term assets and infrastructure. This represents a decrease of 18.9% from the same quarter a year earlier. Against the prior quarter it is up 2.4%.
CLX Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.7B+0.1% | $1.7B-0.8% | $1.4B-18.9% | $2.0B+4.5% | $1.7B-8.0% | $1.7B-15.3% | $1.8B+27.1% | $1.9B-5.7% |
| Cost of Revenue | $948.0M+2.6% | $951.0M+0.3% | $833.0M-12.8% | $1.1B+4.4% | $924.0M-11.8% | $948.0M-15.7% | $955.0M+11.8% | $1.0B-11.9% |
| Gross Profit | $722.0M-3.0% | $722.0M-2.2% | $596.0M-26.1% | $924.0M+4.5% | $744.0M-2.9% | $738.0M-14.8% | $807.0M+51.7% | $884.0M+2.6% |
| R&D Expenses | $27.0M0.0% | $29.0M-6.5% | $28.0M-9.7% | $32.0M-3.0% | $27.0M-15.6% | $31.0M-3.1% | $31.0M+6.9% | $33.0M-13.2% |
| SG&A Expenses | $229.0M-14.2% | $262.0M-6.4% | $277.0M-1.4% | $296.0M+10.4% | $267.0M-11.3% | $280.0M-13.0% | $281.0M+1.8% | $268.0M-18.5% |
| Interest Expense | $27.0M+17.4% | $25.0M+13.6% | $23.0M+9.5% | $22.0M+4.8% | $23.0M+4.5% | $22.0M-15.4% | $21.0M0.0% | $21.0M0.0% |
| Income Tax | $65.0M+3.2% | $54.0M+25.6% | $25.0M-66.2% | $74.0M+37.0% | $63.0M+687.5% | $43.0M+7.5% | $74.0M+1750.0% | $54.0M-3.6% |
| Net Income | $187.0M+0.5% | $157.0M-18.7% | $80.0M-19.2% | $332.0M+53.7% | $186.0M+464.7% | $193.0M+107.5% | $99.0M+350.0% | $216.0M+22.7% |
| EPS (Basic) | $1.54+2.0% | $1.29-16.8% | $0.65-18.8% | $2.69+54.6% | $1.51+468.3% | $1.55+106.7% | $0.80+370.6% | $1.74+21.7% |
| EPS (Diluted) | $1.54+2.7% | $1.29-16.2% | $0.65-18.8% | $2.68+54.9% | $1.50+465.9% | $1.54+105.3% | $0.80+370.6% | $1.73+21.8% |
| Diluted Shares (Avg) | 122M-1.8% | 122M-2.2% | 123M-1.3% | N/A | 124M-0.1% | 125M0.0% | 125M0.0% | N/A |
Not reported in any period shown, so not listed: Operating Income, EBITDA.
CLX Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $6.4B+16.8% | $5.6B+0.6% | $5.5B+0.6% | $5.6B-3.3% | $5.5B-5.0% | $5.6B-5.6% | $5.5B-8.2% | $5.8B-3.3% |
| Current Assets | $2.7B+66.7% | $1.7B+5.9% | $1.7B+7.6% | $1.6B-0.9% | $1.6B-4.3% | $1.6B-9.5% | $1.6B-17.5% | $1.6B-11.3% |
| Cash & Equivalents | $1.2B+425.2% | $227.0M-21.7% | $166.0M-40.3% | $167.0M-17.3% | $226.0M+3.2% | $290.0M-18.3% | $278.0M-46.3% | $202.0M-45.0% |
| Short-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Inventory | $588.0M-7.4% | $608.0M+2.7% | $577.0M-2.9% | $523.0M-17.9% | $635.0M-5.8% | $592.0M-9.6% | $594.0M-16.3% | $637.0M-8.5% |
| Long-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Goodwill | $1.2B+0.6% | $1.2B+1.0% | $1.2B-0.5% | $1.2B+0.1% | $1.2B-0.6% | $1.2B-2.6% | $1.2B-1.0% | $1.2B-1.9% |
| Total Liabilities | $6.3B+19.2% | $5.6B+2.2% | $5.4B+2.2% | $5.1B-3.4% | $5.3B-4.1% | $5.5B-4.1% | $5.3B-10.0% | $5.3B-5.4% |
| Current Liabilities | $3.2B+46.4% | $2.3B+35.7% | $2.2B+41.5% | $1.9B+21.9% | $2.2B+16.7% | $1.7B-14.4% | $1.6B-29.1% | $1.6B-17.9% |
| Non-Current Liabilities | $3.2B+0.7% | $3.2B-13.3% | $3.2B-14.6% | $3.2B-14.2% | $3.2B-14.5% | $3.7B+1.6% | $3.7B+1.7% | $3.7B+1.2% |
| Long-Term Debt | $2.5B+0.2% | $2.5B+0.1% | $2.5B+0.1% | $2.5B+0.1% | $2.5B+0.1% | $2.5B+0.2% | $2.5B+0.2% | $2.5B+0.2% |
| Total Equity | -$67.0M-348.1% | -$125.0M-204.9% | -$22.0M-136.7% | $321.0M-2.1% | $27.0M-70.3% | -$41.0M-177.4% | $60.0M+262.2% | $328.0M+49.1% |
| Retained Earnings | $223.0M+125.3% | $190.0M+179.4% | $200.0M+545.2% | $432.0M+72.8% | $99.0M+191.2% | $68.0M-71.8% | $31.0M-89.6% | $250.0M-57.1% |
Not reported in any period shown, so not listed: Accounts Receivable.
CLX Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$122.0M-142.7% | $311.0M+72.8% | $93.0M-57.9% | $294.0M-13.5% | $286.0M+57.1% | $180.0M+17.6% | $221.0M+1005.0% | $340.0M-20.9% |
| Depreciation & Amortization | $58.0M+5.5% | $55.0M+3.8% | $56.0M+3.7% | $57.0M-3.4% | $55.0M-5.2% | $53.0M-7.0% | $54.0M-11.5% | $59.0M-4.8% |
| Stock-Based Compensation | $15.0M-37.5% | $24.0M-11.1% | $10.0M-23.1% | N/A | $24.0M | $27.0M | $13.0M0.0% | N/A |
| Capital Expenditures | $43.0M-18.9% | $42.0M-20.8% | $36.0M-7.7% | $75.0M-7.4% | $53.0M-3.6% | $53.0M+1.9% | $39.0M+62.5% | $81.0M-3.6% |
| Free Cash Flow | -$165.0M-170.8% | $269.0M+111.8% | $57.0M-68.7% | $219.0M-15.4% | $233.0M+83.5% | $127.0M+25.7% | $182.0M+4650.0% | $259.0M-25.1% |
| Investing Cash Flow | -$43.0M+18.9% | -$43.0M+20.4% | -$34.0M-138.2% | -$76.0M+6.2% | -$53.0M-39.5% | -$54.0M-63.6% | $89.0M+487.0% | -$81.0M0.0% |
| Financing Cash Flow | $1.1B+476.6% | -$210.0M-92.7% | -$59.0M+75.1% | -$279.0M-2.2% | -$299.0M-7.6% | -$109.0M+57.9% | -$237.0M-252.9% | -$273.0M-20.3% |
| Dividends Paid | $150.0M0.0% | $151.0M0.0% | $151.0M0.0% | $150.0M+0.7% | $150.0M0.0% | $151.0M+0.7% | $151.0M+1.3% | $149.0M+2.1% |
| Share Buybacks | $0 | $127.0M-15.3% | $129.0M+20.6% | $75.0M | $0 | $150.0M | $107.0M | $0 |
CLX Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 43.2%-1.4pp | 43.2%-0.6pp | 41.7%-4.1pp | 46.5%0.0pp | 44.6%+2.4pp | 43.8%+0.3pp | 45.8%+7.4pp | 46.5%+3.8pp |
| Net Margin | 11.2%+0.1pp | 9.4%-2.1pp | 5.6%0.0pp | 16.7%+5.4pp | 11.2%+14.0pp | 11.5%+6.8pp | 5.6%+4.0pp | 11.3%+2.6pp |
| Return on Equity | N/A | N/A | N/A | 103.4%+37.6pp | 688.9%+744.9pp | N/A | 165.0% | 65.8%-14.2pp |
| Return on Assets | 2.9%-0.5pp | 2.8%-0.7pp | 1.5%-0.3pp | 6.0%+2.2pp | 3.4%+4.3pp | 3.5%+1.9pp | 1.8%+1.4pp | 3.8%+0.8pp |
| Current Ratio | 0.84+0.1x | 0.74-0.2x | 0.76-0.2x | 0.84-0.2x | 0.74-0.2x | 0.94+0.1x | 1.00+0.1x | 1.03+0.1x |
| Debt-to-Equity | N/A | N/A | N/A | 7.74+0.2x | 91.96+64.7x | N/A | 41.37 | 7.56-3.7x |
| Asset Turnover | 0.260.0x | 0.300.0x | 0.26-0.1x | 0.360.0x | 0.300.0x | 0.300.0x | 0.32+0.1x | 0.330.0x |
| FCF Margin | -9.9%-23.8pp | 16.1%+8.5pp | 4.0%-6.3pp | 11.0%-2.6pp | 14.0%+7.0pp | 7.5%+2.5pp | 10.3%+10.6pp | 13.6%-3.5pp |
Not reported in any period shown, so not listed: Operating Margin.
Note: The current ratio is below 1.0 (0.84), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Clorox Company CLX | FY2025 | $7.1B | $810.0M | 11.4% | $9.7B | 18/100 |
| Church & Dwight Co., Inc. CHD | FY2025 | $6.2B | $736.8M | 11.9% | $22.4B | 56/100 |
| Hims & Hers Health, Inc. HIMS | FY2025 | $2.3B | $128.4M | 5.5% | $6.8B | 50/100 |
| Kimberly-Clark Corp. KMB | FY2025 | $16.4B | $2.0B | 12.3% | $31.4B | 52/100 |
| The Estee Lauder Companies Inc. EL | FY2026 | $15.0B | $182.0M | 1.2% | $33.3B | 36/100 |
| Colgate-Palmolive Company CL | FY2025 | $20.4B | $2.1B | 10.5% | $67.2B | 59/100 |
Where Clorox Company Ranks
Frequently Asked Questions
What is Clorox Company's annual revenue?
Clorox Company (CLX) reported $7.1B in total revenue for fiscal year 2025. This represents a 0.2% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Clorox Company's revenue growing?
Clorox Company (CLX) revenue grew by 0.2% year-over-year, from $7.1B to $7.1B in fiscal year 2025.
Is Clorox Company profitable?
Yes, Clorox Company (CLX) reported a net income of $810.0M in fiscal year 2025, with a net profit margin of 11.4%.
How much debt does Clorox Company have?
As of fiscal year 2025, Clorox Company (CLX) had $167.0M in cash and equivalents against $2.5B in long-term debt.
What is Clorox Company's gross margin?
Clorox Company (CLX) had a gross margin of 45.2% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is Clorox Company's net profit margin?
Clorox Company (CLX) had a net profit margin of 11.4% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
Does Clorox Company pay dividends?
Yes, Clorox Company (CLX) paid $4.88 per share in dividends during fiscal year 2025.
What is Clorox Company's return on equity (ROE)?
Clorox Company (CLX) has a return on equity of 252.3% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Clorox Company's free cash flow?
Clorox Company (CLX) generated $761.0M in free cash flow during fiscal year 2025. This represents a 57.6% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Clorox Company's operating cash flow?
Clorox Company (CLX) generated $981.0M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Clorox Company's total assets?
Clorox Company (CLX) had $5.6B in total assets as of fiscal year 2025, including both current and long-term assets.
What are Clorox Company's capital expenditures?
Clorox Company (CLX) invested $220.0M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Clorox Company spend on research and development?
Clorox Company (CLX) invested $121.0M in research and development during fiscal year 2025.
What is Clorox Company's current ratio?
Clorox Company (CLX) had a current ratio of 0.84 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.
What is Clorox Company's debt-to-equity ratio?
Clorox Company (CLX) had a debt-to-equity ratio of 7.74 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Clorox Company's return on assets (ROA)?
Clorox Company (CLX) had a return on assets of 14.6% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Clorox Company's P/E ratio?
Clorox Company (CLX) trades at 12.9x earnings, its market capitalization divided by net income of $756.0M net income, trailing 12 months to March 31, 2026. The market capitalization is $9.7B as of Oct 3, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Clorox Company's price-to-sales ratio?
Clorox Company (CLX) trades at 1.4x sales, its market capitalization divided by revenue of $6.8B revenue, trailing 12 months to March 31, 2026. The market capitalization is $9.7B as of Oct 3, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Clorox Company's Piotroski F-Score?
Clorox Company (CLX) has a Piotroski F-Score of 7 out of 9, indicating strong financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Clorox Company's earnings high quality?
Clorox Company (CLX) has an earnings quality ratio of 1.21x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is Clorox Company?
Clorox Company (CLX) scores 18 out of 100 on our Financial Health Score, indicating weak standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.